Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26579386 | 0.83 | CNR2 (0.41) | CNR2SMN1; SMN2CA1CA2CA4 | |
| SCHEMBL26579393 | 0.82 | CNR2 (0.43) | CNR2SMN1; SMN2CA1CA2CA4 | |
| SCHEMBL26579398 | 0.81 | CNR2 (0.40) | CNR2SMN1; SMN2CA1CA2CA4 | |
| SCHEMBL24305789 | 0.79 | CNR2 (0.50) | CNR2DAOTP53POLB | |
| SCHEMBL26579431 | 0.76 | CNR2 (0.37) | CNR2 | |
| SCHEMBL25326358 | 0.76 | CNR2 (0.47) | CNR2DAO | |
| SCHEMBL26579425 | 0.74 | CNR2 (0.44) | CNR2SMN1; SMN2BRD4BRDTDAO | |
| SCHEMBL26579411 | 0.74 | CNR2 (0.42) | CNR2SMN1; SMN2POLB | |
| SCHEMBL26579408 | 0.74 | PTGS1 (0.41) | CNR2SMN1; SMN2POLB | |
| SCHEMBL26579422 | 0.72 | CNR2 (0.46) | CNR2DAOHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331672-A1 | 6-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME | CNG BIO CO., LTD. (KR) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331672-A1 | 6-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME | NGF, BDNF, NTRK2 | CNR2 412/4885SMN1; SMN2 4/4885CA1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.